V Ramasubramanian

Prof. V Ramasubramanian


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
DJDivya Rakesh Joshi
Divya Rakesh Joshi
RGRam Gopalakrishnan
Ram Gopalakrishnan
CSC. Selvi
C. Selvi
NSNandini Sethuraman
Nandini Sethuraman
VYV.R. Yamunadevi
V.R. Yamunadevi
Paul ThangarajPaul Thangaraj
Paul Thangaraj

15 June 2026 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
PCPugazhvanan Cr
Pugazhvanan Cr
VKVidya Krishna
Vidya Krishna
NSNandini Sethuraman
Nandini Sethuraman
SPSenthur Nambi P
Senthur Nambi P
VRV Ramasubramanian
V Ramasubramanian
RGRam Gopalakrishnan
Ram Gopalakrishnan

1 January 2023 in Journal of Clinical Infectious Diseases Society
Verified
Journal Article
Open access
VRV Ramasubramanian
V Ramasubramanian

12 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
STSubhash Todi
Subhash Todi
PSPrachee Sathe
Prachee Sathe
VRV Ramasubramanian
V Ramasubramanian
SSSubramanian Swaminathan
Subramanian Swaminathan
DTDeepak Talwar
Deepak Talwar
HTHarish Thanusubramanian
Harish Thanusubramanian
There is limited real-world data from India examining the treatment characteristics, safety, and efficacy of ceftazidime-avibactam against Gram-negative organisms especially multidrug-resistant pathogens including Carbapenem-Resistant Enterobacterales and Carbapenem-Resistant Pseudomonas. In this retrospective study, the real-world treatment patterns, effectiveness, and safety of ceftazidime-avibactam in treating Gram- negative infections were assessed. Data was extracted from electronic health records of adult patients admitted to the hospital with documented Gram-negative infection who had received treatment for at least 48 hours with ceftazidime-avibactam as a part of routine clinical management. Among the 189 patients, on day 3, clinical symptoms improvement was recorded in 79.6% of patients. Clinical success was achieved in 79.5% and 76.3% of assessed patients on day 7 and day 14/End-of-treatment, respectively. Microbiological success was reported in 76% of patients on day 7 and in 60.3% of patients on day 14 or EOT. The mean treatment duration of ceftazidime-avibactam therapy was 6.92 (± 4.1) days. No new safety concerns were identified. In conclusion, this study provides real-world evidence on treatment patterns and clinical outcomes associated with ceftazidime-avibactam in India, complementing the previously reported literature. The results suggest ceftazidime-avibactam is an effective and tolerable option for the management of Gram-negative infections in critically ill patients.

1 October 2023 in Journal of Clinical Infectious Diseases Society
Verified
Journal Article
Open access
MRMadhumitha Ramabhadran
Madhumitha Ramabhadran
VRV Ramasubramanian
V Ramasubramanian
Immunization has been a quintessential part of preventive health saving millions of lives from Vaccine preventable diseases. Adult immunization has also been accepted as an important intervention mandated by immunosenescence and newer co-morbidities faced by adults. However, there has been little headway in establishing adult immunization as an integral aspect of health care for older adults in India. There have been several challenges identified for this scenario. Apart from limited guidelines for vaccinating adults, poor awareness, limited access, vaccine hesitancy and expense play an important role. Though customized guidelines for the Indian population is warranted along with improving awareness about vaccines in the adult population, access to care through adult vaccines are mandatory to establish a functional system. Apart for reiterating vaccines that are most useful for the Indian adults, this commentary outlines the various facets of setting up an adult vaccine clinic in the Indian context.

16 October 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PKParvaiz Koul
Parvaiz Koul
RDRaja Dhar
Raja Dhar
BVBalaji Medical Veeraraghavan
Balaji Medical Veeraraghavan
VRVijai Kumar Ratnavelu
Vijai Kumar Ratnavelu
RGRandeep Guleria
Randeep Guleria
NKNamrata Kulkarni
Namrata Kulkarni
Background: Pneumococcal disease imposes a substantial public health burden in India, particularly among older adults and individuals with chronic or immunocompromising conditions. Although the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine are available, the emergence of non-PCV13 serotypes has highlighted the need for broader serotype coverage. The approval of the 20-valent pneumococcal conjugate vaccine (PCV20) offers expanded serotype coverage and the potential to simplify adult vaccination strategies. Methods: A multidisciplinary expert panel convened to develop evidence-informed expert opinions on PCV20 use in adults. A narrative literature review (2010–2025), a structured pre-meeting web-based survey, and structured discussions using the Nominal Group Technique were conducted. Expert opinions were refined, reviewed, and approved by all panel members. Results: Based on the available evidence and expert deliberations, the panel supported single-dose PCV20 for adults aged ≥50 years and at-risk individuals aged 18–49 years. The panel also provided specialty-specific recommendations to facilitate the implementation of PCV20 in routine clinical practice across diverse adult populations in India. Conclusions: These multidisciplinary expert opinions provide practical guidance for PCV20 use in Indian adults and are intended to complement, not replace, the formal national recommendations and to support informed clinical decision-making for adult pneumococcal vaccination in India, while acknowledging remaining uncertainty regarding effectiveness, implementation, affordability, and the need for further India-specific evidence.